GleamWall
中文EN

CGTX COGNITION THERAPEUTICS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1455365 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY42.9%
TTM EPS YoY66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.6%
ROA-40.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets15.9%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$37.19M$41.68M
SG&A expense$10.61M$12.29M
Operating income-$47.80M-$53.97M
Pretax income$23.49M$33.97M
Income tax$0$0
Net income-$23.49M-$33.97M
EBITDA-$47.76M-$53.86M
EPS (basic)-0.32-0.86
EPS (diluted)-0.32-0.86
Weighted avg. shares (diluted)72.77M39.73M
Balance sheet
Cash & equivalents$36.81M$25.01M
Current assets$47.99M$29.55M
PP&E, net$93,000$181,000
Total assets$48.39M$30.23M
Current liabilities$13.92M$11.14M
Total liabilities$14.12M$11.48M
Shareholders' equity$34.27M$18.75M
Shares outstanding88.90M59.85M
Cash flow statement
Operating cash flow-$24.59M-$28.47M
Capital expenditure—$4,000
Free cash flow—-$28.48M
Investing cash flow$9,000-$4,000
Financing cash flow$36.57M$23.57M
Depreciation & amortization$36,000$107,000
Stock-based compensation$2.09M$3.75M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.